Thursday, 11 November 2010

Stanozolol




In some countries, this medicine may only be approved for veterinary use.


In the US, Stanozolol (stanozolol systemic) is a member of the drug class androgens and anabolic steroids and is used to treat Angioedema.

US matches:

  • Stanozolol

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A14AA02

CAS registry number (Chemical Abstracts Service)

0010418-03-8

Chemical Formula

C21-H32-N2-O

Molecular Weight

328

Therapeutic Categories

Anabolic

Androgen

Chemical Name

2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17ß)-

Foreign Names

  • Stanozololum (Latin)
  • Stanozolol (German)
  • Stanozolol (French)
  • Estanozolol (Spanish)

Generic Names

  • Stanozolol (OS: USAN, JAN, DCF, BAN)
  • Stanozololo (OS: DCIT)
  • Androstanazole (IS)
  • Stanazol (IS)
  • Stanazolol (IS)
  • Stanozolol (PH: BP 2010, USP 32, Ph. Eur. 6)
  • Stanozololum (PH: Ph. Eur. 6)

Brand Names

  • Menabol
    CFL, India


  • Neurabol Caps.
    Cadila Gehört zu Zydus, India


  • Stanabolic (veterinary use)
    Ilium Veterinary Products, Australia


  • Stanazol (veterinary use)
    RWR Veterinary Products, Australia; Vetpharm, New Zealand


  • Stargate (veterinary use)
    Acme, Italy


  • Winstrol V (veterinary use)
    Pharmacia & Upjohn vet, United States


  • Winstrol
    Desma, Spain; Sanofi-Aventis, Bahrain; Sanofi-Aventis, Egypt; Sanofi-Aventis, Kuwait; Sanofi-Aventis, Lebanon; Sanofi-Aventis, Qatar; Sanofi-Aventis, Saudi Arabia; Sanofi-Synthelabo, United Arab Emirates; Sanofi-Synthelabo, Cyprus; Sanofi-Synthelabo, Jordan

International Drug Name Search

Glossary

BANBritish Approved Name
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

No comments:

Post a Comment